Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2006-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1535-7163.MCT-05-0164PMID 16546987
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib

  2005cited by this paper
• Mitochondria as cancer drug targets.

  2004cited by this paper
• Granulocyte Macrophage Colony-stimulating Factor Signaling and Proteasome Inhibition Delay Neutrophil Apoptosis by Increasing the Stability of Mcl-1*

  2004cited by this paper
• Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro‐apoptotic bax and inducing caspase‐3‐mediated cleavage of poly(ADP‐ribose) polymerase (PARP)

  2004cited by this paper
• Downregulation of the antiapoptotic MCL‐1 protein and apoptosis in MA‐11 breast cancer cells induced by an anti‐epidermal growth factor receptor–Pseudomonas exotoxin a immunotoxin

  2004cited by this paper
• Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1

  2004cited by this paper
• The Bcl-2 family: roles in cell survival and oncogenesis

  2003cited by this paper
• Results of triple therapy with interferon‐alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in early chronic phase

  2003cited by this paper
• Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.

  2002cited by this paper
• Cytotoxic mechanism of the ribotoxin alpha-sarcin. Induction of cell death via apoptosis.

  2001cited by this paper
• Cytotoxic mechanism of the ribotoxin α‐sarcin

  2001cited by this paper
• Apoptotic response to homoharringtonine in human wt p53 leukemic cells is independent of reactive oxygen species generation and implicates Bax translocation, mitochondrial cytochrome c release and caspase activation

  2001cited by this paper
• Bcl‐2 family: Life‐or‐death switch

  2000cited by this paper
• Apoptosis is rapidly triggered by antisense depletion of MCL-1 in differentiating U937 cells.

  2000cited by this paper
• Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells.

  2000cited by this paper
• The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability

  2000cited by this paper
• The first semi-synthesis of enantiopure homoharringtonine via anhydrohomoharringtonine from a preformed chiral acyl moiety☆☆☆

  1999cited by this paper
• BCL-2 family members and the mitochondria in apoptosis.

  1999cited by this paper
• Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia.

  1999cited by this paper
• Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients.

  1998cited by this paper
• MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2.

  1993cited by this paper
• Homoharringtonine is safe and effective for patients with acute myelogenous leukemia.

  1992cited by this paper
• Interim assessment

  1990cited by this paper
• Alkaloid homoharringtonine inhibits polypeptide chain elongation on human ribosomes on the step of peptide bond formation

  1989cited by this paper

• Multicenter retrospective analysis of the short-term efficacy and safety of the VAH regimen in the treatment of acute myeloid leukemia.

  2025cites this paper
• Rational combination of homoharringtonine to selectively target FLT3-ITD acute myeloid leukemia through synthetic lethality.

  2025cites this paper
• 高三尖杉酯碱联合维奈克拉、阿扎胞苷治疗初诊急性髓系白血病的疗效及安全性初步分析

  2025cites this paper
• Proteostasis Disruption in Inherited Bone Marrow Failure Syndromes.

  2025cites this paper
• Homoharringtonine enhances cytarabine-induced apoptosis in acute myeloid leukaemia by regulating the p38 MAPK/H2AX/Mcl-1 axis

  2024cites this paper
• Homoharringtonine in the treatment of acute myeloid leukemia: A review

  2024cites this paper
• Antiproliferative Activity of Cephalotaxus Esters: Overcoming Chemoresistance.

  2024cites this paper
• Understanding MDS stem cells: Advances and limitations.

  2024cites this paper
• Homoharringtonine: updated insights into its efficacy in hematological malignancies, diverse cancers and other biomedical applications

  2024influential citation
• Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial

  2023cites this paper
• Synthesis of portimines reveals the basis of their anti-cancer activity

  2023cites this paper
• Comparison of efficacy between homoharringtonine, aclarubicin, cytarabine (HAA) and idarubicin, cytarabine (IA) regimens as induction therapy in patients with de novo core binding factor acute myeloid leukemia

  2023cites this paper
• The GSK3β/Mcl-1 axis is regulated by both FLT3-ITD and Axl and determines the apoptosis induction abilities of FLT3-ITD inhibitors

  2023cites this paper
• Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study

  2023cites this paper
• Homoharringtonine induces apoptosis of mammary carcinoma cells by inhibiting the AKT/mTOR signaling pathway.

  2023cites this paper
• Novel Approaches to Treatment of Acute Myeloid Leukemia Relapse Post Allogeneic Stem Cell Transplantation

  2023cites this paper
• Inhibition of the CDK2 and Cyclin A complex leads to autophagic degradation of CDK2 in cancer cells

  2022cites this paper
• Mechanism of immunomodulatory drug resistance and novel therapeutic strategies in multiple myeloma

  2022cites this paper
• High efficacy of azacitidine combined with homoharringtonine, idarubicin, and cytarabine in newly diagnosed patients with AML: A single arm, phase 2 trial

  2022cites this paper
• Inhibition of the CDK2 and Cyclin A complex leads to autophagic degradation of CDK2 in cancer cells

  2022cites this paper
• Homoharringtonine inhibited breast cancer cells growth via miR-18a-3p/AKT/mTOR signaling pathway

  2021cites this paper
• Therapeutic effects of an innovative BS-HH-002 drug on pancreatic cancer cells via induction of complete MCL-1 degradation

  2021cites this paper
• Homoharringtonine Synergized with Gilteritinib Results in the Downregulation of Myeloid Cell Leukemia-1 by Upregulating UBE2L6 in FLT3-ITD-Mutant Acute Myeloid (Leukemia) Cell Lines

  2021cites this paper
• Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma

  2021cites this paper
• Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.

  2021cites this paper
• The translational repressor 4E-BP1regulates RRM2 levels and functions as a tumor suppressor in Ewing Sarcoma Tumors

  2020cites this paper
• Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia

  2020cites this paper
• Heightened protein-translation activities in mammalian cells and the disease/treatment implications

  2020cites this paper
• Hypoxia-induced SETX links replication stress with the unfolded protein response

  2020cites this paper
• The efficacy and safety of a homoharringtonine-based protocol for children with acute myeloid leukemia: A retrospective study in China

  2020cites this paper
• Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy

  2020cites this paper
• Homoharringtonine synergy with oridonin in treatment of t(8; 21) acute myeloid leukemia

  2019cites this paper
• Homoharringtonine, an approved anti-leukemia drug, suppresses triple negative breast cancer growth through a rapid reduction of anti-apoptotic protein abundance.

  2019cites this paper
• Homoharringtonine Induces Apoptosis in Human Colorectal Carcinoma HCT116 Cells Via Downregulation of Wnt/β‐Catenin Signaling Cascade

  2019cites this paper
• Synergistic cytotoxicity of homoharringtonine and etoposide in acute myeloid leukemia cells involves disrupted antioxidant defense

  2019cites this paper
• Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells

  2019cites this paper
• Acute myeloid leukemia in an 86-year-old man with AML1/ETO treated with Homoharringtonine and Arsenic Trioxide

  2019cites this paper
• The spliceosome inhibitors isoginkgetin and pladienolide B induce ATF3-dependent cell death

  2019cites this paper
• Homoharringtonine enhances idarubicin-induced apoptosis via regulation of the mitochondrial pathway

  2019cites this paper
• Homoharringtonine regulates the alternative splicing of Bcl-x and caspase 9 through a protein phosphatase 1-dependent mechanism

  2018cites this paper
• Rapid induction of p62 and GABARAPL1 upon proteasome inhibition promotes survival before autophagy activation

  2018cites this paper
• The Mitochondrial Apopto tic Effectors BAX / BAK Activate Caspase-3 and-7 to Trigger NLRP 3 Inflammasome and Caspase-8 Driven IL-1 b Activation Graphical

  2018cites this paper
• A Review of Omacetaxine: A Chronic Myeloid Leukemia Treatment Resurrected

  2018cites this paper
• Natural scaffolds in anticancer therapy and precision medicine.

  2018cites this paper
• Development of a stress response therapy targeting aggressive prostate cancer

  2018cites this paper
• The Mitochondrial Apoptotic Effectors BAX/BAK Activate Caspase-3 and -7 to Trigger NLRP3 Inflammasome and Caspase-8 Driven IL-1β Activation.

  2018cites this paper
• Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms

  2018cites this paper
• GanDouLing combined with Penicillamine improves cerebrovascular injury via PERK/eIF2α/CHOP endoplasmic reticulum stress pathway in the mouse model of Wilson’s disease

  2018cites this paper
• Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers

  2017cites this paper
• Cephalotaxus Alkaloids

  2017cites this paper
• ATF4 promotes angiogenesis and neuronal cell death and confers ferroptosis in a xCT-dependent manner

  2017cites this paper
• The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia

  2016cites this paper
• A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia

  2016cites this paper
• Natural Product Anticancer Drugs

  2016cites this paper
• Inhibitory effect of magnetic Fe3O4 nanoparticles coloaded with homoharringtonine on human leukemia cells in vivo and in vitro

  2016cites this paper
• Identification of genetic variants or genes that are associated with Homoharringtonine (HHT) response through a genome-wide association study in human lymphoblastoid cell lines (LCLs)

  2015cites this paper
• High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma

  2015cites this paper
• Inhibition of myeloid cell leukemia‐1: Association with sorafenib‐induced apoptosis in human mucoepidermoid carcinoma cells and tumor xenograft

  2015cites this paper
• Homoharringtonine increases intestinal epithelial permeability by modulating specific claudin isoforms in Caco-2 cell monolayers.

  2015cites this paper
• A comparative proteomic study of Homoharringtonine-induced apoptosis in leukemia K562 cells

  2015cites this paper
• Bcl-2 Family: Translational Aspects

  2015cites this paper
• An unexpected pentacarbonyl chromium complexation of a cyano group of the ABC core of cephalotaxine

  2015cites this paper
• Type I interferons mediate pancreatic toxicities of PERK inhibition

  2015cites this paper
• Chronic Myeloid Leukemia— What Else is there Beyond Protein Kinase Inhibitors?

  2014cites this paper
• Omacetaxine mepesuccinate in chronic myeloid leukemia

  2014cites this paper
• Cancer wars: natural products strike back

  2014cites this paper
• Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia

  2014cites this paper
• Homoharringtonine and omacetaxine for myeloid hematological malignancies

  2014cites this paper
• Role of matriptase (ST14) in chronic myeloid leukaemia.

  2014cites this paper
• Subcutaneous omacetaxine mepesuccinate in patients with chronic myeloid leukemia in tyrosine kinase inhibitor-resistant patients: review and perspectives.

  2014cites this paper
• Current and Emerging Therapies Targeting Translation

  2014cites this paper
• ATF4 Protects Against Neuronal Death in Cellular Parkinson's Disease Models by Maintaining Levels of Parkin

  2013cites this paper
• Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells.

  2013cites this paper
• Omacetaxine mepesuccinate (synribo) – newly launched in chronic myeloid leukemia

  2013cites this paper
• Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial.

  2013cites this paper
• Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic‐phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors

  2013cites this paper
• Omacetaxine Mepesuccinate: A New Treatment Option for Patients With Chronic Myelogenous Leukemia

  2013cites this paper
• Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors

  2013influential citation
• Catenin and AKT are promising targets for combination therapy in cute myeloid leukemia

  2013cites this paper
• β-Catenin and AKT are promising targets for combination therapy in acute myeloid leukemia.

  2013cites this paper
• FGF-2 prevents cancer cells from ER stress-mediated apoptosis via enhancing proteasome-mediated Nck degradation.

  2013cites this paper
• Omacetaxine mepesuccinate for management of chronic myeloid leukemia

  2013cites this paper
• Targeting aberrant kinase activity in myeloid leukaemias

  2013cites this paper
• Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.

  2013cites this paper
• Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common β-subunit c of cytokine receptors

  2012cites this paper
• Treatment of Chronic Myeloid Leukaemia: Current Practice and Future Prospects

  2012cites this paper
• Dual Targeting of the Cyclin/Rb/E2F and Mitochondrial Pathways in Mantle Cell Lymphoma with the Translation Inhibitor Silvestrol

  2012cites this paper
• Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.

  2012cites this paper
• Integrated Stress Response Modulates Cellular Redox State via Induction of Cystathionine γ-Lyase

  2012cites this paper
• High-dose homoharringtonine versus standard-dose daunorubicin is effective and safe as induction and post-induction chemotherapy for elderly patients with acute myeloid leukemia: a multicenter experience from China

  2012cites this paper
• Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor

  2012cites this paper
• 1 Treatment of Chronic Myeloid Leukaemia : Current Practice and Future Prospects

  2012cites this paper
• Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T 315 I mutation

  2012cites this paper
• Emerging therapies in chronic myeloid leukemia.

  2012cites this paper
• Emerging therapeutics targeting mRNA translation.

  2012cites this paper
• The impact of the unfolded protein response on human disease

  2012cites this paper
• Endoplasmic reticulum stress, the unfolded protein response, autophagy, and the integrated regulation of breast cancer cell fate.

  2012cites this paper
• Investigation into omacetaxine solution stability for in vitro study.

  2012cites this paper
• Omacetaxine as an anticancer therapeutic: what is old is new again.

  2011cites this paper
• Bcl-xL Is a Dominant Antiapoptotic Protein that Inhibits Homoharringtonine-Induced Apoptosis in Leukemia Cells

  2011influential citation